Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator BCL9, a complex that drives oncogene expression in multiple cancers where aberrant Wnt/β-catenin pathway signaling is observed.
Lead Product(s): ST316
Therapeutic Area: Oncology Product Name: ST316
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
The funding will be used to investigate pharmacodynamic biomarkers for ST316, a first-in-class beta-catenin antagonist, and evaluate the impact of ST316 on the tumor microenvironment (TME) in patient-derived cancer models.
Lead Product(s): ST316
Therapeutic Area: Oncology Product Name: ST316
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 04, 2023
Details:
ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator BCL9, a complex that drives oncogene expression in multiple cancers where aberrant Wnt/β-catenin pathway signaling is observed.
Lead Product(s): ST316
Therapeutic Area: Oncology Product Name: ST316
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The grant allows to further evaluate the efficacy of ST101 in patient-derived breast cancer models, which will inform patient selection criteria to enhance ST101's ability to treat multiple types of difficult cancers.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2022
Details:
ST101 is peptide antagonist of C/EBPβ with dual MOA, antagonism of C/EBPβ promotes favorable immune tumor microenvironment by inhibiting formation of immunosuppressive myeloid-derived suppressor cells and cytotoxic activity in tumor cells.
Lead Product(s): ST101,Temozolomide
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
ST101 is showing promising results in GBM with a PR, which we have confirmed with repeat scans per mRANO and using an independent radiology reviewer.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
ST101, a first-in-class antagonist of C/EBPβ, has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
FDA has granted FTD to ST101 for the treatment of recurrent glioblastoma, currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021